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Although sleep abnormalities in general and sleep-related breathing disorders (SBD) in par-
ticular are quite common in healthy children; their presence is notably under-recognized.
Impaired sleep is a frequent problem in subjects with inborn errors of metabolism as well
as in a variety of genetic disorders; however, they are commonly either missed or under-
estimated. Moreover, the complex clinical presentation and the frequently life-threatening
symptoms are so overwhelming that sleep and its quality may be easily dismissed. Even
centers, which specialize in rare genetic-metabolic disorders, are expected to see only
few patients with a particular syndrome, a fact that significantly contributes to the under-
diagnosis and treatment of impaired sleep in this particular population. Many of those
patients suffer from reduced life quality associated with a variable degree of cognitive
impairment, which may be worsened by poor sleep and abnormal ventilation during sleep,
abnormalities which can be alleviated by proper treatment. Even when such problems
are detected, there is a paucity of publications on sleep and breathing characteristics of
such patients that the treating physician can refer to. In the present paper, we provide
an overview of sleep and breathing characteristics in a number of rare genetic–metabolic
disorders with the hope that it will serve as a reminder for the medical professional to
look for possible impaired sleep and SBD in their patients and when present to apply the
appropriate evaluation and treatment options.
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INTRODUCTION
Sleep disorders cause significant morbidity in the general pop-
ulation. While an impressive progress has been made in the
recognition and treatment of such disorders in adults, the same
disorders which affect as many as 30% of healthy children are still
under-recognized (1).
Inborn errors of metabolism (IEM) and non-metabolic genetic
disorders manifest mostly during early childhood with progres-
sive neuromuscular, skeletal, and/or neuro-cognitive abnormali-
ties. The affected children suffer frequently from abnormal sleep
accompanied by disordered breathing. It is conceivable that under-
recognition of sleep problems in this particular young popula-
tion is much more pronounced due to the rarity and complex
symptomatology of such disorders.
Sleep and breathing are tightly linked. Human sleep is induced
and modulated by specialized central neuronal networks; however,
recent evidence suggests that there are also local areas of the brain
involved in sleep–wake modulation (2). Normal breathing is reg-
ulated by central and peripheral chemo- and mechano-receptors
that are responsible for the reduction in the slope of the ven-
tilatory responses to hypoxia and hypercapnia during sleep as
compared to wakefulness. As a result, the minute ventilation drops
progressively reaching its minimum during the phasic stage of
rapid eye movement (REM) sleep (3).
Sleep-related breathing disorders (SBD) are quite common
in the general population. Snoring and obstructive sleep apnea
(OSA) are the main SBD for which children and adults are now-a-
days referred to sleep disorders centers and as such are considered
the “bread and butter” of sleep medicine. Nevertheless, children
and young adults with hereditary disorders associated with SBD
are only rarely evaluated by such centers. Thus, even in a sleep
center with special interest in hereditary disorders, very few such
patients are expected to be evaluated. The specialist who is dealing
with a child or a young adult afflicted with one of those disorders
is so busy taking care of his young patient’s serious and complex
medical and behavioral problems that the issue of sleep quality is
either overseen or masked by the severity of other symptoms. This
is also true in the case of the general practitioner and the adult
neurologist when they “takes over” the care of such a child as he
gets older but has not “grown out” of his sleep problems.
Out of the numerous metabolic/genetic disorders, we have
elected to review in-brief those with well-documented impaired
sleep as well as SBD in an attempt to provide the primary physi-
cians and the specialists taking care of such patients as well as the
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sleep practitioners with a relatively “quick reference” to the nature
of the sleep disorder that their patient may suffer from. We hope
that in this way, we will help the interested reader to apply the
appropriate method of evaluation and provide treatment, which
may improve the life quality, if not prolong the shortened life
expectancy of their patients.
INBORN ERRORS OF METABOLISM
Inborn errors of metabolism are rare genetically determined bio-
chemical disorders caused by a single gene defect that result in a
deficient enzyme or protein and consequently lead to characteris-
tic clinical and biochemical abnormalities. The diseases caused by
IEM vary considerably in their clinical and pathological aspects.
They commonly present during infancy, early childhood, and
more rarely during early adulthood. The clinical diagnosis of IEM
may be easily reached by physicians familiar with those disorders,
although a biochemical confirmation is required to establish a
sound diagnosis, which in a number of those disorders may lead to
successful therapy. In addition to the well-known clinical and lab-
oratory manifestations of those disorders, there are also associated
and frequent sleep abnormalities, which have not gained sufficient
interest and insight. Many individuals with IEM are retarded, rest-
less, and difficult to communicate. Those features may lead quite
often to the conclusion that the patients are “problematic sleepers”
and there is no need for costly and in many patients an almost
impossible task to study their sleep by nocturnal polysomnogra-
phy (NPSG) at the sleep center or at home using a portable sleep
recording device. Moreover, there is a tendency to regard retarded
people, many of them with IEM, as impaired sleepers without
the need to look for the precise cause and nature of the disorder.
Considering the fact that the majority of the disorders, which we
have included in this review are associated with skeletal anomalies
affecting the chest wall and the upper airway (UA) tract, it is not




The mucopolysaccharidoses (MPSs) consist of rare heterogeneous
genetically determined lysosomal storage disorders caused by defi-
cient or inactive enzymes necessary for the breakdown of gly-
cosaminoglycans (GAGs). GAGs are complex carbohydrates com-
posed of repeats of disaccharide units, which form long unranked
polysaccharides. As a result, GAGs are stored within the lysosomes
and cause systemic organ damage. Seven different types of MPS,
i.e., I, II, III, IV, VI, VII, IX and additional subtypes of III and
IV are known. All types are autosomal recessive (AR) except MPS
II, which is autosomal dominant (AD) (Hunter syndrome) (4).
The world wide prevalence of MPS is 0.6–5:100,000 and the life
expectancy is about 20 years (5). The cardinal abnormalities are
musculoskeletal and cardiovascular in the form of systemic and
pulmonary hypertension and congestive heart failure. Another
clinical feature is moderate–severe cognitive impairment, mainly
in MPS III and to a lesser extent in MPS I, II, and VII, which
is related mainly to accumulation of GAGs in the perivascular
spaces of the brain. There is also neuropathological evidence of
ongoing neurodegeneration in several subtypes of MPS (6). UA
obstruction is common in all forms of MPS due to adenotonsil-
lar enlargement, large and protruded tongue, reduced retropalatal
and retroglossal space, narrow trachea and nasal airway, short neck
and small thoracic cage. Those anatomical changes are caused by
excessive accumulation of GAGs in the UA. Recently, analysis of
the UA in children with MPS with the acoustic reflection method
showed significant UA obstruction due to reduction of the min-
imal cross-sectional area of the subglottic region, the narrowest
part of the UA. This finding was associated with an increase in
airway resistance (7). Those anatomical features are responsible
for the high frequency of OSA, which deleteriously affects cardio-
vascular morbidity in MPS. Unfortunately, complete PSG studies
were reported in a small number of patients. Nashed et al. (8) have
studied 14 children and adolescents, most of them with MPS I,
with NPSG trying to document not only the basic characteristics
of nocturnal sleep and breathing features but also to evaluate the
influence of enzyme replacement therapy (ERT) given to three of
those patients. OSA was found in 7 (64%) of the 11 untreated
children (mean age 5.2 years) and was scored as moderate–severe
in 6 despite prior adenotonsillectomy. In the three children who
receive ERT, a significant reduction in apnea hypopnea index
(AHI) was noticed. Central sleep apnea was present in only one
patient with MPS I. In a quite recent home sleep study on 19
patients with various subtypes of MPS, 18 were found to suf-
fer from OSA (11 with severe OSA) (9). Thus, early recognition
of OSA and proper treatment in those patients may reduce the
high cardiovascular mortally and perhaps improve their daily
vigilance.
GLYCOGEN STORAGE DISEASE
This group of disorders is caused by functionally defective enzymes
involved in either breakdown or synthesis of glycogen. Glycogen
storage disease (GSD) affects mainly the liver and muscle. Out
of the presently recognized 11 subtypes of GSD, 8 affect muscles
and are entitled “muscle glycogenoses.” Of those, GSD II, known
also as Pompe’s disease (PD), (OMIM #232300), affects signifi-
cantly respiratory muscles and is associated with SBD. PD is an
AR disorder caused by a deficiency of the lysosomal enzyme α-
glucosidase (acid maltase) resulting in lysosomal accumulation of
glycogen in almost all tissues, however, the first clinical manifes-
tations are frequently due to dysfunction of cardiac and skeletal
muscles. The three phenotypes of the disease are determined by
the amount of residual acid maltase activity, which is dismal in
the fatal infantile form. In the adult onset form, the residual
enzyme activity is higher; therefore, the resulting disorder is rela-
tively benign. There is also an intermediate childhood onset form.
Respiratory muscles are involved in all phenotypes. In the infan-
tile form, pronounced obstructive hypertrophic cardiomyopathy
and skeletal muscle weakness and atrophy are caused by storage of
glycogen within muscles and spinal motor neurons. The disease
course is rapidly progressive leading to fatal cardio-respiratory
failure before the children reach their first birthday. The inter-
mediate childhood form presents with delayed motor milestones
detected at the age of 6–12 months when progressive proximal
muscle weakness without signs of cardiomyopathy are noted. The
main cause of death is respiratory failure (10). In the relatively
mild adult form, proximal muscle weakness may not be evident
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until the age of 20–60 years while respiratory problems appear ear-
lier and are much more prominent. It is typical for those patients
to be able to carry their heavy oxygen tank on their way to the ini-
tial neuromuscular evaluation. Respiratory failure is progressive
in all forms of PD. In a recent retrospective study, 17 patients aged
0.5–17.5 months who suffered from the infantile form, underwent
at least a single NPSG study. Six had mild and one had moder-
ate OSA. The mean sleep efficiency was 73%. Interestingly, even
in infants without symptoms of SBD, hypoventilation and OSA
were recorded. This finding led the authors to recommend rou-
tine PSG in every infant with PD (11). Only 30% of adult patients
with PD complain initially of daytime somnolence and morning
headaches (12), and the main PSG findings are related to severity
of daytime somnolence. In four patients with childhood onset PD,
Nabatame et al. (13) have recorded hypopneas and apneas during
NREM sleep with accentuation during REM sleep regardless of
the presence of muscular symptoms. Three patients with NPSG
proven SBD received non-invasive intermittent positive pressure
ventilation during sleep over 2 years. Although SBD resolved and
life quality improved, the impaired respiratory functions were not
similarly affected. Patients with the adult form had abnormal AHI,
which markedly decreased after institution of mechanical ventila-
tion. Only a weak correlation was found between respiratory and
muscle functions, which was relatively preserved while respira-
tory functions were failing (14). Worsening of SBD during REM
sleep is not a specific feature of PD being common in variety of
neuromuscular disorders (15).
ASPARTYLGLUCOSAMINURIA
Aspartylglucosaminuria (AGU) (OMIM #258406) is a rare and
severe AR lysosomal storage disorder that affects the central ner-
vous system, skeleton, and connective tissue. The main charac-
teristic clinical feature is mental deterioration. AGU is caused
by deficient activity of the lysosomal enzyme glycosylasparagi-
nase due to a mutated aspartylglucosaminidase gene located on
chromosome 4. As a result, series of glycoasparagines with an
aspartylglucosamine moiety at the reducing end are accumulated
in tissues and body fluids (16). Premature death occurs at the age of
35–40 years (17). Adolescent patients suffer from bouts of inabil-
ity to fall asleep accompanied by confusion lasting few days (18).
About 25% of the patients suffer from maladaptive sleep behavior,
which was attributed to mental retardation (19). We could not find
accounts of PSG studies in the English written literature. A single
sleep questionnaires study of 81 patients disclosed difficulties in
sleep setting in the young patients and severely fragmented night
sleep in older patients (20). Although the reason for the disordered
sleep pattern is not clear, the presence of hypointense appearance
of the thalami on T2-weighted MRI images (21), which may be
caused by the metabolic impairment, can perhaps explain this
particular sleep pattern.
NEURONAL CEROID LIPOFUSCINOSIS
This is a group of heterogeneous inherited progressive degenera-
tive diseases, which affect the brain and retina due to lysosomal
accumulation of ceroid-lipofuscin, an extremely inert and stable
lipopigment that displays typical ultrastructural patterns. Muta-
tions in nine different genes are known to cause neuronal ceroid
lipofuscinosis (NCL). The age of clinical onset varies from birth
to adulthood. The etiology of NCL remains elusive.
The juvenile onset form (CLN3), known also as Batten–Mayou
syndrome (OMIM #204200), is one of the most common child-
hood onset neurodegenerative disorders in all ethnic groups except
in Jews (22). The main clinical features are visual loss first noticed
at 7 years of age, which progress to total blindness at the age of
13–14 years, cognitive decline, and seizures. Life span is signifi-
cantly shortened and disordered sleep is quite common. According
to sleep questionnaires, 55% of 42 patients were found to suffer
from difficult sleep stetting, numerous awakenings, and night-
mares (23). In a clinical and NPSG study of 28 patients, 6–27 years
of age, total sleep time, sleep efficiency, and REM sleep duration
were decreased while the percentage of sleep stage 1 and the num-
ber of awakenings were increased (24). The fact that all patients
were practically blind raised the possibility that the findings were
secondary to poor vision. This assumption was based on the fact
that sleep disturbances and abnormal melatonin rhythm are more
common in blind children without light perception (LP) than
in those with LP (25, 26). Although melatonin rhythm was not
studied in the NCL cohort mentioned above, the sleep struc-
ture abnormalities documented were irrespective of the degree
of severity of visual impairment.
WILSON’S DISEASE
This AR disorder of copper metabolism (OMIM #277900) is
manifested by systemic storage of copper due to deficiency of a
membrane-bound copper transporting P-type ATPase. Patients
with Wilson’s disease (WD) carry hundreds of mutations in the
ATPB7 gene located on chromosome 13 (27, 28). As a result there
is a decreased incorporation of copper into ceruloplasmin, the
copper binding protein, leading to free copper accumulation espe-
cially in the liver, cornea, and nuclei of the putamen and globus
pallidus. Neurological symptoms are present in about 40% of the
patients and consist of a variety of progressive involuntary move-
ments that appear during childhood and very rarely after the age
of 40 years. Disordered sleep is quite common. Neshimalova et al.
(29) used sleep questionnaires in 55 adults with confirmed WD
and performed NPSG followed by Multiple Sleep Latency Test
(MSLT) in 24. The results were compared to those obtained from
25 healthy age- and sex-matched controls. Forty-one (80%) of the
patients reported daytime tiredness, excessive daytime sleepiness,
cataplexy-like episodes, and poor nocturnal sleep. In the majority
of the patients, those problems appeared concomitantly with the
clinical onset while only three patients stated that their sleep prob-
lems started before they became symptomatic. Interestingly, the
subjective sleep complaints were unrelated to hepatic or neuro-
logical morbidity. On NPSG, sleep efficiency, total sleep time, and
latencies to sleep stage 1, 2 and NREM sleep were decreased. Peri-
odic limb movements (PLM) were recorded in 40%. On MSLT,
shortened or borderline sleep latencies were found in a third of
the patients. Sleep onset REM periods on NPSG or MSLT were
not found. Once more, the results of nocturnal NPSG and MSLT
could not be related to disease severity. In a study from India (30),
the clinical and NPSG characteristics of sleep were studied in 25
patients. Total sleep time, sleep efficiency, duration of slow wave
sleep, and REM sleep percentage were reduced while sleep latency
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was prolonged. The patients who were on de-coppering treatment
had prolonged REM latency and mixed apnea. The differences
between the two-mentioned studies may imply the presence of
genetic heterogeneity, different treatment regimens, and/or differ-
ences in the extent of copper storage and its location in the central
neural pathways involved in normal sleep.
FRIEDREICH ATAXIA
Friedreich ataxia (FRDA) (OMIM #229300) is one of the com-
monest AR ataxias affecting 1:50,000 births (31). It is characterized
by progressive loss of sensory neurons in the spinal cord and dorsal
root ganglia associated with ataxia, sensory neuropathy, kyphosco-
liosis, cardiomyopathy, and premature death. FRDA is caused by
expansion of TAA triple nucleotide repeats within the intron of
the FRDA gene (Frataxin) located on chromosome 9. Fatigue is
a frequent complains in FRDA (32). A recent NPSG study of 21
patients with an Epworth Sleepiness Scale of >8 showed that 21%
of the participants suffered from OSA. The authors suggest that
OSA in FRDA is related to disease duration and the presence of
reduced respiratory muscle strength in conjunction with scoliosis
and poor posture (33).
CHROMOSOMAL ANOMALIES
RETT SYNDROME
Rett syndrome (RTS) (OMIM #312750) affects 1:10,000 female
infants, 6–18 months of age and manifests with loss of acquired
speech, stereotype“hand clapping,” deceleration of head and brain
growth, autistic behavior, emotional withdrawal, lack of eye con-
tact, seizures, and severe “dysautonomia” in the form of respira-
tory, cardiac, and gastrointestinal dysfunction. About 25% of the
affected girls die prematurely of cardio-respiratory failure (34).
More than 95% of the girls show a loss-of-function mutation in the
gene encoding Methyl-CpG-binding protein 2 (MeCP2) located
on chromosome X. Over 200 different mutations are known to be
present in patients with RTS. Breathing abnormalities are common
and severe enough to be included in the clinical diagnostic criteria
of the syndrome. The characteristic abnormalities are breath hold-
ing spells and apneas coupled with subtle bradycardia followed by
exaggerated tachycardia. Those are pronounced when awake and
to a much lesser extent during sleep (35). In 30 affected girls, PSG
showed only subtle breathing abnormalities during REM sleep
in contrast to marked breathing abnormalities when awake. This
unexpected finding suggests that in RTS, an imbalance may exist
between the behavioral and metabolic control of respiration. Dur-
ing wakefulness, marked breathing abnormalities may be caused
by impaired cortical respiratory control (behavioral). Indeed, dur-
ing wakefulness, the girls have bouts of hyperventilation followed
by apnea (post-hyperventilation apnea, PHA), which occur after a
happy and/or exciting event. During the event, they appear com-
fortable in spite of being cyanotic. This peculiar behavioral pattern
is similar to that observed in children with congenital central
hypoventilation syndrome (CCHS) whose apneic episodes were
coined “happy hypoxia” (36). Considering the marked obsessive
characteristics of girls with RTS, it seems logical that the attacks of
PHA are also obsessive (“voluntary”). This may explain the con-
trast between daily severe breathing abnormalities when awake
and the almost normal breathing when asleep. Although PHA is
only rarely seen in healthy individuals, it is often present when
the cerebral cortex control is subdued by sedation, anesthesia, age-
related frontal lobe dysfunction and dementia. Interestingly, this
unique breathing pattern is so common in RTS while it is very rare
in other forms of mental retardation and other types of autistic
disorders. A clear-cut explanation for its presence in RTS is still
in need.
DOWN SYNDROME
Down syndrome (DS) (OMIM #190685), the most frequent form
of mental retardation, is caused by trisomy of all or a critical
portion of chromosome 21. A large number of the characteristic
features of DS such as midfacial hypoplasia, mandibular hypopla-
sia, glossoptosis, abnormally small UA, superficially positioned
tonsils; relative tonsillar and adenoidal encroachment and hypo-
tonia of the UA are all known risk factors for OSA. Thus, it is not
surprising that OSA may be present during early infancy and con-
tribute to the developmental delay of the affected infants. Indeed,
among a cohort of 108 patients 1–18 years of age, 64.7% had SBD
(37). OSA is present in 30–55% of children with DS and reaches
a peak of 94% during adulthood (38). The worsening of OSA is
related not only to age and obesity but also to increased rate of DS
associated hypothyroidism. Patients with DS compared to normal
developing age-matched subjects, have greater bedtime resistance,
sleep anxiety, increased short awakenings from night sleep, brux-
ism, night talking, and daytime sleepiness. Considering the high
frequency of tonsillar and adenoidal hypertrophy in children with
DS, it is somewhat surprising that tonsillectomy and adenoidec-
tomy improved some parameters of OSA, but the outcome was
inferior to that of non-DS children. This fact implies that besides
the enlarged tonsils and adenoids, the additional bony and soft
tissue anomalies of the UA tract mentioned above may play an
important role in the high frequency of SBD in DS. This assump-
tion is supported by an earlier NPSG study on 10 institutionalized
patients aged 6–32.2 years with a mean body mass index (BMI) of
29.4 in whom the authors excluded UA pathology. The outstand-
ing finding was the marked preponderance of central apnea in this
particular group of patients (89.4% central and 9.4% obstructive)
(39). The discrepancy between the results of the earlier and recent
study mentioned above may reflect the selectivity bias as well as
the small sample size of the earlier study.
FRAGILE X SYNDROME
Fragile X syndrome (FXS) (OMIM #300624) is a X-linked
syndrome considered the most common inherited cognitive–
behavioral disorder in boys while girls are very rarely affected.
The silenced mutated fragile X mental retardation-1 (FMR1) gene
product is a cytosine–guanine–guanine (CGG) triplet expansion
with ≥200 repeats. Animal studies have indicated that normal
sleep–wake cycle is significantly blunted in the absence of frag-
ile X mental retardation (FMR) protein (40). Sleep problems are
quite frequent in the affected children and may be noticed in
many before the age of 3 years. Those consist of difficult night
setting, restless interrupted sleep, early awakening, and excessive
daytime sleepiness (41). Unfortunately, only few subjects with
FXS underwent NPSG, because of the difficulties of performing
such a study in retarded children with difficulties in maintaining
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sufficient nocturnal sleep. In a cohort of 14 boys with a mean age
of 13.1 years, reduced time in bed, higher percentage of stage 1,
NREM, and a lower percentage of REM sleep were documented.
Interestingly, when compared to children with DS who are also
mentally retarded but have a quite docile behavior pattern, the
patients with FXS showed the most disrupted sleep microstruc-
ture when their sleep architecture and NREM sleep alterations
were analyzed by means of the Cyclic Alternating Pattern (42).
FRAGILE X ASSOCIATED TREMOR/ATAXIA SYNDROME
This is a different rare condition related to FXS (OMIM #300623)
affecting elderly male carries with <200 CGG repeats (premu-
tation). The patients suffer from late onset progressive ataxia,
intentional tremor, and cognitive decline. Female carriers are very
rarely affected (43). In a relatively recent study from a center spe-
cializing in FXTAS, history compatible with OSA was looked for
during the clinical evaluation and when positive the results of
NPSG were obtained from the physicians who had referred the
patient for a sleep study. Among 118 patients with FXTAS, 31.4%
suffered from OSA as compared to 13.8% of 174 patients with
the premutation but without FXTAS and 8.6% of 174 normal
controls (44).
ANGELMAN SYNDROME
This AR neurodevelopmental disorder, known also as the “happy
puppet syndrome,” consists of craniofacial dysmorphism, micro-
cephaly, severe mental and speech retardation, ataxia of gait,
puppet-like jerky movements, bouts of involuntary laughter, and
epilepsy. In the majority of the patients, there is an absence of a
maternal contribution to the imprinted region on chromosome
15q11–q13 (OMIM #105830). Sleep/wake rhythm disorders, mul-
tiple nocturnal awakenings, and difficult sleep onset are reported
in 20–80% of the patients. The characteristic published NPSG
findings in Angelman syndrome (AS) are based on a small num-
ber of patients. When compared to children with primary mental
retardation with and without epilepsy, 14 children with AS showed
higher percentage of wakefulness after sleep onset, awakenings
from sleep, and a longer sleep and REM latencies. PLM was quite
frequent in both AS and the non AS retarded subjects. SBD was
present in AS and its severity as judged by AHI>5 was not signif-
icantly different in the three examined groups. It was concluded
that the sleep abnormalities recorded in AS are mostly related to
mental retardation, epilepsy, and its drug treatment (45).
PRADER–WILLI SYNDROME
Prader–Willi syndrome (PWS) (OMIM #176270) is a rare AD dis-
order occurring in 1:10,000–1:25,000 live births. It is caused by
deletion or disruption of a gene or several genes on the proximal
long arm of the paternal chromosome 15 or maternal uniparental
disomy 15. The clinical characteristics consist of diminished fetal
activity, infantile hypotonia and failure to thrive. Somewhat later
progressive significant weight gain due to ravenous appetite result-
ing in morbid obesity, short stature, small hands and feet, hypogo-
nadotropic hypogonadism and mental retardation are recognized
(46). SBD in the form of OSA is quite common. Sleep is often
impaired leading to excessive daytime sleepiness in about 70–85%
of the patients (47). Based on MSLT results, 40–50% of adult
patients suffer from severe daytime sleepiness (48). Abnormal
sleep consists of shortened latency and duration of REM sleep,
sleep-onset REM periods, OSA, and sometimes “narcoleptic like”
symptoms. Recently, Sedky et al. (49) reviewed 14 studies on 224
children with PWS who underwent NPSG as part of an assessment
of OSA. In 179 (79.91%), the diagnosis of OSA was confirmed.
Severe OSA was present in 24.58% of the adolescent patients.
Narcolepsy was diagnosed in 35.71% of the study population.
Adenotonillectomy was helpful but residual OSA was still present
post-operatively. The etiology of impaired sleep in PWS is proba-
bly multifactorial considering the close association of obesity and
OSA. However, an additional role of hypothalamic dysfunction
present in PWS cannot be ruled out.
WILLIAMS–BEUREN SYNDROME
This AR neurodevelopmental disorder (OMIM #612547) is the
result of a microdeletion at a specific region of chromosome 7.
The prevalence of Williams–Beuren syndrome (WBS) was esti-
mated at 1:7500. The affected children suffer from neurological,
cognitive, cardiovascular, musculoskeletal, and endocrine abnor-
malities. Mild-moderated mental retardation and symptoms simi-
lar to those of children with attention deficit hyperactivity disorder
(ADHD) are the main neurocognitive characteristics. Parents are
frequently bothered by their child’s disordered sleep. Mason et al.
(50) studied 35 youngsters aged 2–18 years with sleep and behav-
ioral questionnaires and NPSG. The findings were compared to
those obtained from matched healthy subjects. The main symp-
toms reported were difficulty falling asleep, increased restless-
ness, and increased respiratory-related arousals. NPSG indicated
decreased sleep efficiency, increased time spent awake after sleep
onset and increased slow wave sleep. There was a good correlation
between parental ratings of arousals/awakenings during the night
and the NPSG findings. The authors were unable to confirm earlier
observations of increased rate of PLM in their patients. Although
52% of their subjects showed symptoms compatible with ADHD,
which could explain most of the findings, there was no clear cut
association between parental report of “ADHD like” symptoms
and the sleep disturbances revealed in this particular large and
recent study.
SMITH–LEMLI–OPITZ SYNDROME
This AR rare syndrome (OMIM #270400) affects 1:20,000–80,000
live born American Caucasian infants who present with variable
clinical features and severity (51). The typical phenotype is a child
with characteristic peculiar facial appearance, cleft palate, micro-
cephaly, hypotonia, cardiac defects, prenatal and postnatal growth
retardation, postaxial polydactyly, two to three toe syndactyly, and
hypogenitalism. Malformations of the brain and lung are less com-
mon (52). Rarely, patients may present with minor anomalies and
enjoy almost normal development (53). Smith–Lemli–Opitz syn-
drome (SLOS) is caused by deficiency of 7-dehydrocholesterol
(7-DHC) reductase, encoded by the DHCR7 gene located on chro-
mosome 11. As a result, cholesterol synthesis is impaired leading
to marked hypocholesterolemia (54). In 1998, an abnormal sleep
pattern was reported in a significant number of affected chil-
dren diagnosed on clinical basis (53). More recently, a systematic
evaluation of sleep characteristics in 18 patients with biochemical
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confirmation of the diagnosis disclosed the presence of nocturnal
snoring in half of the patients, labored breathing in 11%, a variety
of abnormal sleep behavior abnormalities, and excessive daytime
sleepiness (51).
It is intriguing to postulate that the low serum cholesterol
in patient with SLOS may play a role in their impaired sleep.
This assumption can be ruled out as none of our 14 young
patients with marked hypocholesterolemia due to abetalipopro-
teinemia (Bassen–Kornzweig Syndrome – BKS, OMIM #200100)
complained of impaired sleep. Moreover, a literature search using
the key words, hypercholesterolemia,BKS and sleep, failed to reveal
such an association. The presence of facial anomalies, cleft palate
and muscle hypotonia could contribute to snoring and breathing
abnormalities mentioned above. It should be noted that without
objective studies such as NPSG, the complete spectrum of sleep
impairment in SLOS cannot be fully determined.
SEGAWA’S DISEASE
This is treatable form of AD hereditary dystonia associated with
a unique sleep disorder (OMIM #605407). The disease is caused
by a large number of mutations at the guanosine triphosphate
cyclohydrolase 1 (GTPCH1) gene located on chromosome 14
(55). The main clinical characteristics are progressive postural
dystonia with marked diurnal fluctuation. While during the early
morning hours there is only a hint of dystonia, it is getting pro-
gressively pronounced and disabling, reaching a peak of severity
during the early afternoon. The ongoing dystonia is accompa-
nied by uncontrolled urge to sleep. In fact, one of our affected
girls used to fall asleep at about 5p.m. and woke up at about
3–4a.m. to the dismay of the other family members. The motor
disability is not associated with mental or primary psycholog-
ical abnormalities or features of Parkinsonism. Administration
of small doses of l-DOPA results in almost complete normaliza-
tion of the motor impairment as long as treatment is given. One
of our patients successfully treated for 37 years with small doses
of Dopicar® and later Sinemt® had not shown any of the well-
known disabling side effects encountered especially in patients
with early onset Parkinson disease (56). Interestingly, the sus-
tained hypersomnolence that she experienced during childhood
before the initiation of drug treatment which improved her sleep
and vigilance, was replaced during adolescence and adulthood by
severe insomnia and numerous awakenings during the night. The
inability to maintain sufficient nocturnal sleep was resistant to
treatment with a large number of hypnotics, alterations in the
dose of l-DOPA, administration of different dopaminergics and
a variety of SSRI type antidepressants. A repeated NPSG was con-
sistent with reduced sleep efficiency due to frequent awakenings
from sleep stage 2. The results of PSG evaluations in patients
with Segawa’s disease (SD) are variable. This may be due to the
natural course of the disease during which the diurnal varia-
tions in sleep ameliorate with age or due to genetic heterogeneity
caused by the numerous mutations at the gene for SD. Segawa
(57) showed with selective sleep stage deprivation studies that
twitch movements (TM) during REM sleep were reduced by 20%,
perhaps related to the decreased dopaminergic activity in those
patients. An improvement in the impaired sleep symptoms con-
comitantly with an increase in TM was noted with l-DOPA. All
other parameters of the NPSG were normal. Gadoth et al. (58) have
assessed the number of body movements (BMs) during NPSG
recording in 3 girls with the sporadic form of SD (two off and
one on l-DOPA) and 11 of their healthy first degree relatives.
Increased number of BMs was found in the three girls. Both
parents of one girl had increased BMs while six of the parents
and three of the siblings had PLM. In 18 patients with geneti-
cally confirmed SD reported by Van Hove et al. (59), subjective
daytime sleepiness, urge to oversleep and frequent nightmares
were noted. However, both NPSG and MSLT were normal except
for shorter total REM sleep, which was attributed to medication
effect.
SEPIAPTERIN REDUCTASE DEFICIENCY
This AR form of DOPA responsive movement disorder (OMIM
#182125) is caused by mutations in the sepiapterin reductase
(SPR) gene, located on chromosome 2. The encoded SPR par-
ticipates in the tetrahydrobiopterin recycling pathway involved
in the biosynthesis of dopamine and serotonin (60). Symptoms
appear very early in life and may be erroneously diagnosed as
cerebral palsy. The correct diagnosis becomes evident somewhat
later when motor and speech delay, axial hypotonia, dystonia,
weakness, and oculogyric crises with diurnal fluctuation and sleep
benefit are detected. In addition, psychomotor impairment slowly
develops. A striking feature is severe daytime sleepiness (61). In
a 28-year-old patient with sleep abnormalities since early child-
hood, reduced metabolism of serotonin in the cerebrospinal fluid
and flat serum melatonin profile were found. The patient under-
went a sleep interview, wrist actigraphy, sleep log over 14 days
and 48 h continuous sleep, and core temperature monitoring.
Mild hypersomnia with prolonged sleep time (704 min) and ultra-
dian sleep–wake rhythm with sleep occurrence every 11.8± 5.3 h
were documented. Supplementation with 5-hydroxytryptophan
resulted in improved cognition as a consequence of reduction of
total sleep time to 540 min and restoration of serotonin metabo-




Familial dysautonomia (FD), known also as Hereditary Auto-
nomic and Sensory Neuropathy type III (HASN III) (OMIM
#223900), is a rare AR disorder affecting exclusively infants and
children of Jewish Ashkenazi origin with a carrier rate of 1:30,
which increases to 1:18 in families of Polish origin (63). It is
caused by a specific splicing mutation in the IKBKAP gene located
on chromosome 9. The discovery of this mutation made it pos-
sible to reach an accurate prenatal diagnosis, which resulted in a
dramatic reduction in the number of new patients. The patho-
physiology of FD is attributed mainly to a progressive autonomic
neuropathy associated with progressive loss of small myelinated,
and to a lesser extent, unmyelinated fibers. The clinical mani-
festations may be evident at birth and with time the affected
children and young adults suffer from cardiovascular, respira-
tory, gastrointestinal, musculoskeletal, and renal dysfunction. In
addition, marked emotional and behavioral adaptive problems
are present (64). Breathing abnormalities in the form of breath
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holding spells appear during infancy and persist throughout life.
There is an outstanding ability of the affected children to hold their
breath for extended periods of time, which may be responsible for
the high rate of premature sudden death. Both phenomena are the
result of defective responsiveness of the brainstem chemoreceptors
to changes in PaO2 and PaCO2. Severe progressive kyphoscoliosis
and cardiac dysatonomia are significant contributing factors to the
presence of SBD. In addition and probably related are difficulties in
sleep setting and awakening in the morning. Among 13 patients,
5–31 years of age, breath holding spells and difficulties in wak-
ing in the morning were reported by 69% and excessive daytime
sleepiness by 38%. NPSG disclosed the presence of obstructive
and central apneas mainly during stage 2 and REM sleep and also
during sleep stage 3–4 (65).
CONGENITAL CENTRAL HYPOVENTILATION SYNDROME
This is a rare life-threatening AD disorder of central auto-
nomic control of respiration (OMIM #209880). Clinical presen-
tation occurs usually at birth or soon after. Known previously as
“Ondine’s curse,” it is characterized by severe reduction in ventila-
tory sensitivity to hypercapnia both during NREM slow wave sleep,
REM sleep, and wakefulness. The diagnosis requires the presence
of marked hypoventilation during sleep without primary neuro-
muscular, cardiac, respiratory, or brainstem disease. Autonomic
dysfunction outside the central nervous system is also present
in the form of Hirschsprung disease, cardiac arrhythmia, pupil-
lary abnormalities, excessive sweating, and tumors of neural crest
derivatives (66). In more than 90% of the cases, a poly-alanine
repeat expansion due to mutations in the paired-like homeobox
PHOX2B gene located on chromosome 4 is present (67). Although
most of the cases present during early infancy and sometimes
at birth, clinical signs may appear at an older age. The clinical
presentation as well as the phenotype–genotype correlations are
variable. Thus, the disease should be considered in young indi-
viduals with life-threatening paroxysms of cyanosis during sleep,
unexplained seizures, respiratory depression induced by anesthe-
sia, sedation or anti-convulsive drugs, cognitive impairment with
previous cyanotic spells, primary nocturnal hypoxemia associated
with hypercarbia, superior ability to stay underwater, recurrent
pneumonia, and sudden unexplained childhood/infant death. The
exact relation between sleep stage and the timing of hypercar-
bic/anoxic events is of interest, but such data are unfortunately
not available. We were able to find a single comment on PSG done
in one patient, which was summarized as “significant oxygen and
carbon dioxide abnormalities occurring after sleep onset” (68).
SLEEP IN HEREDITARY SKELETAL DEFORMITIES
Dwarfism and gigantism are frequently associated with craniofa-
cial dysmorphism and neurological impairment, both major risk
factors for sleep abnormalities. Out of numerous syndromes com-
prising this group, Achondroplasia and Marfan syndrome (MS)
are the best studied in regard to sleep and breathing characteristics
during sleep.
ACHONDROPLASIA
This AD syndrome (OMIM #100800) is the most common form
of short limb dwarfism with a prevalence of 1:1000–30,000 in
newborns (69). It is caused most commonly by a mutation in the
fibroblast growth factor receptor-3 (FGFR-3) located on chromo-
some 4. Sleep characteristics gained special interest since those
patients are prone to UA obstruction during sleep as well as to
impairment of central respiratory control due to impingement of
the lower brain stem and medulla within the narrow foramen mag-
num. OSA is present in 10% of affected children aged 4 years, and
in 16% of all patients regardless of age (70). Between 10 and 85%
of affected infants and children seek treatment for major respira-
tory difficulty, i.e., OSA, waking cyanotic episodes, and chronic
respiratory insufficiency. The predisposing factors are thoracic
cage restriction and midfacial hypoplasia. In addition, foramen
magnum stenosis caused by dysplastic basiocciput, occipital bone,
and craniovertebral junction with secondary brain stem compres-
sion, may contribute to dysregulation of breathing. Recently, the
sleep characteristics of 29 children and adolescents (median age:
3 years, range 0.4–17.1) were reported. A third underwent UA
surgery previous to the study and 17% had a previous cranio-
cervical decompression for foramen magnum stenosis. Habitual
snoring was reported in 77% and witnessed sleep apnea in 33%.
Nocturnal PSG was considered abnormal in 93% and AHI was
≥10 in 43%. The majority of apneas were obstructive with 22%
central and 5% mixed type. The correlation between symptoms of
SBD and the results of NPSG was poor; however, AHI correlated
well with severity of daytime fatigue (71).
MARFAN SYNDROME (MS)
Marfan syndrome is a rare AD disorder of connective tissue
(OMIM #154700) due to mutations in the gene encoding for
fibrillin-1 (FBN1) located on chromosome 15. The frequency of
MS is 0.01% in the general population. Although connective tis-
sue is globally affected, the clinical manifestations involve the eyes,
lungs, thoracic aorta,dura matter, and skeleton. The main cause for
early mortality is dissection and rupture of the aorta. Sleep com-
plaints such as snoring, apnea, sleep disruption, daytime fatigue,
and difficulties in memory and concentration are common (72).
Craniofacial anomalies such as retrognathia, increased mean neck
circumference, and increased nasal airway resistance were consid-
ered as causing OSA in MS. Interestingly, in a recent study on
a relatively large group of unselected patients, sleep apnea was
found in about 30%, however, about 50% of the apneas were cen-
tral rather than the expected obstructive apneas (73). Considering
the above, it is logical to screen patients with MS for SBD regardless
of the presence of the accepted clinical clues for OSA.
TREACHER COLLINS SYNDROME
This rare AD disorder (OMIM #248390) is one of the several
congenital craniofacial anomalies such as Pierre Robin, Apert,
and Crouzon syndrome, which are associated with severe OSA.
Patients with Treacher Collins syndrome (TCS) carry mutations
in the TCOF1 gene, located on chromosome 5. The classical clinical
features are micrognathia, zygomatico-temporo-maxillary dysos-
tosis, mandibular hypoplasia, choanal atresia, underdevelopment
of the auricles, down slant of the eyelids, coloboma of the eye-
lids, and hypoplasia of the zygomatic bone and lateral orbital
wall. The incidence of TCS is 1:50,000 live births. In about 60%
of the patients, the family history is negative. The abnormalities
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mentioned above explain the high frequency of OSA in those
patients, which ranges from 54% in children to 41% in adults
(74). Surgical relief of airway obstruction is complicated due to
the numerous locations of possible obstruction. Thus, a careful
determination of the most useful site (sites) for reconstructive
surgery is the key to successful outcome.
SLEEP IN HEREDITARY NEUROMUSCULAR DISORDERS
In general, patients with hereditary neuromuscular disorders
(HND) present during childhood and are at risk for sleep-related
hypoventilation leading to sleep hypoxemia, pulmonary hyper-
tension, and secondary cognitive impairment. SBD is not rare
manifesting as severe impairment of respiratory regulation dur-
ing sleep. In addition to OSA, some children with HND suffer
from reduced sensitivity of their central chemoreceptors, which
contributes to SBD. Considering the fact that the largest load of
patients with genetically determined neurometabolic disorders are
those with neuromuscular diseases, which are frequently compli-
cated by SBD, it was interesting to estimate its frequency in a busy
neuromuscular clinic. Labanowski et al. (75) have performed such
a study in the New Mexico Neuromuscular Disorders Clinic. Out
of a total of 306 patients, 54 adults and 10 children agreed to
participate in the study. Of those, 42% suffered from SBD. The
presenting symptoms of SBD in children with HND usually man-
ifest when muscle weakness is still mild. At that stage, there are
no clinical signs of respiratory difficulty during the day or they
are so mild and therefore are often masked by the general concern
about the decreased muscle strength. The children may present
with daytime sleepiness and fatigue, reduced sleep quality, fre-
quent awakenings, morning headaches, mood changes, attention
and learning deficits, failure to thrive and more rarely, noctur-
nal hypoxic seizures. If unrecognized, progression to secondary
polycythemia, hypertension, and heart failure is inevitable (76).
DUCHENNE MUSCULAR DYSTROPHY
Duchenne muscular dystrophy (DMD) (OMIM #310200) affects
boys and very rarely girls. The affected carry mutations in the
dystrophin gene located on chromosome X, which is responsi-
ble for progressive degeneration of muscle fibers. Subsequently,
the affected subjects will become wheel-chair bound at the age of
10–12 years with a life expectancy of 26 years. Dilating cardiomy-
opathy occurs in almost all patients and is the cause of early death
in 10–20% (77). In addition to limb-girdle musculature, there is a
progressive loss of respiratory muscle fibers leading to ineffective
cough, decreased ventilation, recurrent pneumonia, atelectasis,
and respiratory failure during wakefulness and especially during
REM sleep. Respiratory problems are first manifested during sleep
and if detected early and given appropriate treatment, the patients
will enjoy an improved life quality, which is very significant con-
sidering the severity and fatal nature of the disease. SBD is usually
present when forced vital capacity (FVC) is reduced to 65%, thus
FVC monitoring can be useful for appropriate timing of PSG. The
appearance of nocturnal hypoventilation predicts the onset of pro-
gressive daytime hypercapnia some 2 years later. The institution of
non-invasive ventilation (NIV) before the development of day-
time hypercapnia is highly recommended (78). Annual evaluation
of SBD should be initiated when the patient becomes wheel-chair
bound. Dilated cardiomyopathy, which primarily affects the left
ventricle is the cause of death in about 10–20% of the patients.
There is a vicious cycle of events finally leading to right ventricular
failure. Initially, left dilated cardiomyopathy appears accompanied
by dyspnea, which subsequently evolves to central apnea. The pro-
gression of respiratory difficulties will lead to right ventricular
failure accompanied by pulmonary hypertension and respiratory
failure. To delay the appearance of this vicious cycle, the institution
of non-invasive ventilatory support should be considered when
hypercapnia (pCO2 ≥50 mmHg) and/or hemoglobin saturations
remains <92% when awake. Most of the patients will benefit
from NIV while tracheostomy is only rarely justified. Interestingly,
“preventive” nocturnal non-invasive positive pressure ventilation
(NIPPV) should be avoided because patients who received NIPPV
had a decreased survival rate as compared to the untreated patients
(79). Somewhat similar features may be present in other HND
such as the severe form of limb-girdle, facio-scapulo-humoral,
Emery–Dreifuss, and congenital muscular dystrophies.
MYOTONIC MUSCULAR DYSTROPHY TYPE 1 (MMD-1)
This AD multisystem disorder (OMIM #160900) is the most com-
mon form of muscular dystrophy in adults. It is caused by a
heterozygous trinucleotide (“Triplet”) repeat expansion (CTGn)
in the 3′-untranslated region of the dystrophia myotonica pro-
tein kinase gene on chromosome 19. The number of the triplet
repeats predicts the age of onset and eventually the severity of the
disease. Weakness, wasting and myotonia of the facial, oropharyn-
geal, lingual, masticatory, and distal muscles are the characteristic
neuromuscular abnormalities. Daytime hypersomnolence is the
most common sleep-related complaint being present in 70–80%
of patients. The main PSG findings include obstructive and cen-
tral apnea during sleep and wakefulness, PLM, and REM sleep
dysregulation. Symptoms of restless leg syndrome (RLS) are fre-
quently reported (80). Interestingly, some patients who were ade-
quately treated for SBD are still sleepy during the day. In those
patients administration of Modafinil (Provigil®) can be valuable
for improving daytime vigilance (81). When the disease manifests
during childhood and the muscular symptoms are accompanied
by daytime somnolence which is frequently associated with learn-
ing disability, PSG is indicated to detect the presence of OSA and
PLM which are present in about 65% of this particular population
(82). The congenital onset of the disease is the severest form of
MMD-1 manifesting severe skeletal, neuromuscular and cognitive
abnormalities. Thoracic muscle weakness and abnormal cranio-
facial features are the cause of increased UA resistance associated
with mixed central and obstructive apnea (83).
MYOTONIC MUSCULAR DYSTROPHY TYPE 2
This relatively rare AD subgroup of MMD (OMIM #602668) is less
severe than MMD-1. It is characterized by proximal leg and fin-
ger flexor weakness, pain, and stiffness, without significant clinical
myotonia, which is clearly present on electromyography. Patients
with myotonic muscular dystrophy type 2 (MMD-2) have only
mild facial weakness, ptosis, and cognitive impairment associ-
ated with white matter abnormalities. Respiratory muscles are not
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significantly affected while the proximal leg and distal hand mus-
cles, in particular the finger flexors, are early involved. The disease
is caused by a mutated ZNF9 (zinc finger protein 9) gene located
on chromosome 3, resulting in a CCTG unstable repeat expansion.
The repeat length is not a predictor of age of onset and severity of
symptoms as in MMD-1. Sleep characteristics were only recently
studied in eight patients. Excessive daytime sleepiness was reported
by six patients, insomnia by five, excessive fatigue by four, and fea-
tures compatible with RLS by four. NPSG was recorded in five and
showed the presence of OSA in three (84).
SPINAL MUSCULAR ATROPHY
This AR disorder affects infants, children, and adults. Four sub-
types (I-IV) of spinal muscular atrophy (SMA) are recognized.
Types I–II present during infancy, type III during adolescence
and type IV during adulthood. The progressive death of spinal
motor neurons associated with symmetrical muscle wasting and
weakness is caused by deletions and only rarely by mutations in
the survival motor neuron 1 (SMN1) gene located on chromo-
some 5. SMA I, known also as Wording–Hoffman disease (OMIM
#253300), is the second most common neuromuscular disorder in
children affecting 8:100,000 live births. It is also the second in-line
lethal condition of childhood after cystic fibrosis. The clinical onset
becomes evident at about 3 months of age and sometimes even
earlier. Death mainly from pneumonia occurs at about the age of
2 years. Hypercapnia, somnolence, morning headaches, and atten-
tion deficits are seen in children with SMA I–II. They suffer from
hypoventilation due to respiratory muscle weakness and char-
acteristic paradoxical breathing expressed as thoraco-abdominal
asynchrony, which is mostly evident during quite and active sleep.
There are only few reports on nocturnal sleep characteristics and
the effect of NIV on those characteristics. Night sleep was studied
by NPSG in seven children with SBD, six with SMA I, and one
with SMA II. NPSG prior to initiation of NIV showed an increase
in sleep stage 1, 2 concomitant with decreased stage 3, 4 and REM
sleep. Numerous arousals and decreased sleep efficiency were also
noted. Following NIV, the duration of sleep stage 1, 2 decreased
concomitant with an increase in sleep stage III–IV, a tendency
toward longer REM sleep, and a significant decrease in the num-
ber of EEG-arousals (85). The exact timing for institution of NIV
is not yet established as routine respiratory function studies are
usually difficult and annual PSG or overnight oximetry are not
always available. The emerging possibilities of genetic manipula-
tion of SMA using Antisense oligonucleotides, which is useful in
the mouse model of SMA (86) may reinforce the need for early
detection and treatment of respiratory failure and SBD in those
patients.
HEREDITARY CEREBELLAR DEGENERATION
The cerebellum and its central and peripheral connections are
involved not only in motor regulation but also in certain cognitive
functions as well as in sleep. Out of the heterogeneous heredi-
tary cerebellar degeneration (HCD), those with significant sleep
impairment are the dominant spino-cerebellar atrophies (SCA), in
particular type 1,2,3,6. SCA3,known also as Machado–Joseph dis-
ease (OMIM #109150), is the most common AD ataxia. It is caused
by a trinucleotide (CAG n) repeat expansion encoding glutamine
repeats in the ataxin-3 gene (ATXN3) located on chromosome
14. In addition to ataxia, the patients suffer from motor neu-
ron disease, external ophthalmoplegia, Parkinsonism, dystonia,
peripheral neuropathy, and non-motor symptoms such as olfac-
tory, memory, executive, and psychiatric impairment. Complains
of insomnia, excessive daytime sleep, RLS, REM sleep behavior
disorder (RSBD), and sleep apnea are quite frequent. In a recent
clinical and PSG evaluation of 22 patients with average disease
duration of 7.2± 4.6 years, PLM was recorded in 77, REM sleep
without muscle atonia in 73%, RSBD in 59%. 54% reported symp-
toms compatible with RLS (87). Somewhat similar results were
recently reported in 16 Chinese patients (88).
CONGENITAL NEUROPATHIES
HEREDITARY MOTOR AND SENSORY NEUROPATHY
Hereditary motor and sensory neuropathy (HMSN), known also
as Charcot–Marie–Tooth disease (CMTD), is a group of inherited
neuropathies, which differ in their clinical, electrophysiological,
pathological, and genetic features. The vast majority of patients
with AD HMSN carry a mutation responsible for a duplica-
tion of the gene encoding peripheral myelin protein-22 (PMP
22), located on chromosome 17 (HMSM-1A, OMIM #118220).
The prevalence of CMTD is 1:2500 (89). Sleep abnormalities
in the form of OSA and PLM are well known in CMTD. In a
quite recent sleep study on 61 patients with CMT1 (dominant
HMSN), 34 suffered from HMSN-1A, 10 from HMSN-1B (OMIM
#118200) caused by heterozygous mutation in the gene encoding
myelin protein zero (MPZ) located on chromosome 1, and 17 had
HMSN-X1 (OMIM #302800) caused by hemizygous or heterozy-
gous mutation in the GJB1 (Gap Junction Beta 1) gene located
on chromosome X. All patients had subjective reduced nocturnal
sleep quality, daytime hypersomnolence, and significant fatigue.
NPSG disclosed the presence of OSA in 37.7% of all patients.
Interestingly, the severity of OSA was better correlated with the
functional disability of the patients rather than with BMI and
aging. A significant portion of patients had mixed apnea. It was
suggested that the particular tendency for OSA in those patients
may be related to spread of the neuropathy to the pharyngeal
muscles (90).
CONGENITAL MYOPATHIES
This heterogeneous group of non-dystrophic early onset
myopathies is characterized pathologically by presence of pro-
tein aggregates within muscle fibers. Molecular studies proved
that those disorders are expressed as mild to severe phenotypes
with adolescent and even late adult onset. In this heterogeneous
group of disorders, infants and children with nemaline, myotubu-
lar, centronuclear, and protein aggregate myopathies suffer from
SBD due to deformities of the facial bones, severe scoliosis, and
marked weakness of the facial, bulbar, and respiratory muscles.
NEMALINE MYOPTHY
Nemaline myopthy (NM) in its severe form presents at birth with
marked hypotonia, dysphagia, and dyspnea. However, even the
“classical” form may present at birth, during childhood, and even
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early adulthood with milder clinical features. The determinant of
severity is the degree of scoliosis and restrictive lung disease. The
clinical variability of NM is probably due to the fact that the dis-
ease is caused by seven different gene mutations known today. Of
those, the most common is a mutation in the nebulin gene located
on chromosome 2. The clinical heterogeneity was demonstrated
in four patients reported by Sasaki et al. (91). One of the stud-
ied patients suffered from the severe infantile form and the other
three from the benign “classical” form. While the child with the
severe form had breathing abnormalities at birth, the other three
developed an acute respiratory crisis at the ages of 2, 8, and 9 years
when they were still ambulant and muscle weakness was mild.
This discrepancy seems to be rather the rule in NM. Thus, careful
monitoring of respiratory functions is required especially when
such patients show a discrepancy between motor and respiratory
functions. In the above mentioned publication, NPSG was per-
formed in the child with the severe form and in one of the three
with the mild classical form. Apneic spells or irregular thoracic
movements associated with hypercapnia were recorded only dur-
ing REM periods in both children. As mentioned above, patient
with myotubular, centronuclear, and protein aggregate myopathies
are not very different in terms of SBD, which is related to the
severity and distribution of muscle weakness.
CLOSING REMARKS
Although only a portion of all hereditary disorders, which are com-
plicated by sleep and often breathing problems have been included
in this review, we believe that the entities described represent well
the scope of those problems and will provide the reader who may
be asked to evaluate such patients with clues to “ when and how”
should sleep problems be approached. Moreover, detecting and
treating sleep problems in those patients may improve their already
impaired life quality.
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